bivalirudin GPIIb IIIa bivalirudin GPIIb IIIa (N 2994) inhibitor (N 2902) inhibitor (N 3008) (N 2882)

Quadruple

4 Heparin

16 Heparin

heparin

EMEA 2003

REPLACE 2 bleeding site frequency data (bivalirudin versus heparin GPIIb IIIa inhibitor).

Dosage of Heparin

22 Dosage of Heparin

1.6 versus 0.9 respectively).

Before the end of the first year after the entry into force of this Agreement, the Stabilisation and Association Committee shall set up the necessary subcommittees for the adequate implementation of this Agreement.

Other organo inorganic compounds

Anthranilic acid and its salts

Use with low molecular weight and unfractionated heparin

Discontinue unfractionated heparin.

Heparin administration Heparin administration is recommended unless a contraindication (such as a history of thrombocytopaenia associated with use of heparin) is present.

medicines used to prevent blood clotting (warfarin, heparin and dicoumarol)

Angiox was compared with heparin.

In a randomised study of heparin versus placebo (XPRESS) in 1935 adult severe sepsis patients, all treated with drotrecogin alfa (activated), prophylactic heparin did not adversely affect mortality (heparin 28.3 versus placebo 31.9 in the overall ITT population, and heparin 30.3 versus placebo 26.9 in patients with multiple organ dysfunction treated within 24 hours of their first sepsis induced organ dysfunction (n 890)).

e factors in patients with severe hepatic impairment (see section 4.2).

So, your options are, the First Pass Effect refers to the absorption of a drug from its sight of administration or it refers to how the drug reaches its first sight of action.

Antithrombin activity is greatly enhanced by heparin and the anticoagulant effects of heparin depend on the presence of antithrombin.

HIT type II is an illness which can occur after you have received heparin containing medicines.

Patients with Heparin Induced Thrombocytopenia Fondaparinux should be used with caution in patients with a history of HIT.

15 Patients with Heparin Induced Thrombocytopenia Fondaparinux should be used with caution in patients with a history of HIT.

Patients with Heparin Induced Thrombocytopenia Fondaparinux should be used with caution in patients with a history of HIT.

Antithrombotic agent (platelet aggregation inhibitor excl. heparin), ATC code

Approximately 98 of patients (in each of the treatment groups) received antithrombins (heparin, low molecular weight heparin, bivalirudin, or other agent) directly in support of PCI.

bleeding site frequency data for the

In the subgroup of 885 patients who were already receiving prophylactic heparin at study entry, mortality was 26.9 in the group randomised to continue heparin versus 35.6 in the group whose randomisation (to placebo) led to the discontinuation of heparin.

Antithrombin replacement during administration of anticoagulants that potentiate the anticoagulant activity of antithrombin (e. g., heparin, low molecular weight heparin), may increase the risk of bleeding.

Co administration of low dose heparin for prophylaxis of venous thrombotic events (VTE) Low dose heparin for VTE prophylaxis may be co administered with drotrecogin alfa (activated).

ACUITY trial 30 day bleeding endpoints for

Patients with Heparin Induced Thrombocytopenia Fondaparinux does not bind to platelet factor 4 and does not cross react with sera from patients with Heparin Induced Thrombocytopenia (HIT) type II.

ATryn is normally given with heparin (another anti clotting medicine).

Heparin and Rapilysin are incompatible when combined in solution.

Heparin, which is given together with Rapilysin, may also increase bleeding.

Clinical and biological surveillance when antithrombin is used together with heparin, low molecular weight heparin or other anticoagulants which potentiate the anticoagulant activity of antithrombin

Heparins were administered in more than 90 of the patients and the relative rate of bleeding between clopidogrel and placebo was not significantly affected by the concomitant heparin therapy.

It constitutes a certain kind of allergy towards heparin.

These agents include desirudin, fibrinolytic agents, GP IIb IIIa receptor antagonists, heparin, heparinoids, or Low Molecular Weight Heparin (LMWH).

Compagel Gel for Horses contains heparin sodium, levomenthol and hydroxyethyl salicylates.

100g gel contains heparin sodium 50 000 IU levomenthol 0.5 g hydroxyethyl salicylate 5.0 g

ATryn is normally given in association with heparin or low molecular weight heparin.

Bleeding events were more frequent in patients receiving concurrent heparin while undergoing PCI, when ACT exceeded 350 seconds (see section 4.4, heparin use).